检索问题
肺炎的研究进展
肺炎作为一种严重的呼吸道感染，在全球范围内造成了显著的健康负担。随着研究的不断深入，科学界对肺炎的认识和治疗手段有了许多新的进展和发现。以下是关于肺炎研究进展的详细分析。
1. 泳医学研究的增长
根据一项关于2001年至2015年间肺炎研究的全球文献计量分析，研究显示在此期间，肺炎相关的出版物数量显著增加，从2001年的981篇增长到2015年的1977篇。此外，美国在这一领域的科研生产是最高的，占所有研究的38.49%；其次是英国（7.18%）和日本（5.46%）。这一增长趋势反映出科学界对肺炎问题的日益关注。
研究的面积包括以细菌性肺炎、肺炎球菌肺炎及呼吸机相关性肺炎等为主要研究主题，这些研究的目的不仅是为了更好地了解肺炎的病因、流行病学和临床表现，还为了改进现有的治疗和预防策略。
2. 临床转化研究的进展
在临床转化领域，肺囊虫肺炎（Pneumocystis pneumonia，PcP）在免疫功能低下的人群中仍然是一种主要的致病因素，特别是在HIV感染者中。近年来的研究表明，肺囊虫的定植不仅在免疫功能低下群体中普遍存在，也与慢性阻塞性肺疾病等严重的肺部疾病相关联。这一发现强调了重视肺囊虫的临床研究的重要性，并建议未来的研究应更好地理解其临床意义及其在公共卫生中的影响。
3. 针对儿童的肺炎死亡率问题
在尼日利亚，肺炎被认为是五岁以下儿童死亡的主要原因之一。研究发现，影响儿童肺炎死亡率的因素包括营养不良和空气污染等。该研究通过深入访谈和焦点小组讨论，探讨了医务工作者对肺炎的看法以及应对策略。这反映出在面对公共卫生挑战时，必须结合政策和实际情况制定有效的干预措施。
4. UK的肺炎研究投资情况
根据一项针对1997年至2013年间英国肺炎研究投资的系统分析，尽管肺炎的研究投资在2011至2013年间有所增加，但与其它感染性疾病相比其投资仍显不足。例如，虽然肺炎的研究经费从约2880万英镑提高至相对较高的数目，但相比于结核病和流感等疾患者，却仍然较低。这一现象提示了公共政策在资源分配时需进一步优化，以应对肺炎所造成的健康危机。
5. 社区获得性肺炎（CAP）的长期预后
社区获得性肺炎（CAP）是导致杭美国感染性疾病死亡的首要原因之一。一项关于CAP患者长期预后的研究表明，尽管有些研究关注短期死亡率，长期生存率同样关键，尤其是在患者出院后的几个月及之后。同时，不同的风险因素（如年龄、性别、基础疾病、肺炎类型和病情严重性）都会显著影响CAP患者的长期生存率。这一发现推动了公共卫生计划的实施，以缩小此领域的研究与实践之间的差距。
结论
综上所述，肺炎的研究随着时间的推移已显示出积极的增长趋势。尽管在多个方面取得了一定成就，公共卫生政策和研究资源的优化仍然是提升肺炎患者生存率的关键。对肺炎的深入探索有助于医务工作者理解该疾病的复杂性，从而制定更有效的预防和治疗措施。同时，了解地域性差异和人群特征也对肺炎的研究和临床实践至关重要。这一领域需要继续紧跟科研的最新动态，以更好地应对全球范围内肺炎带来的挑战。
References
1A snapshot of pneumonia research activity and collaboration patterns (2001-2015): a global bibliometric analysis.PubMed
José M Ramos-Rincón, Héctor Pinargote-Celorio, Isabel Belinchón-Romero, et al.
BMC Med Res Methodol. 2019 Sep 5;19(1):184. doi: 10.1186/s12874-019-0819-4.
BACKGROUND: This article describes a bibliometric review of the scientific production, geographical distribution, collaboration, impact, and subject area focus of pneumonia research indexed on the Web of Science over a 15-year period. METHODS: We searched the Web of Science database using the Medical Subject Heading (MeSH) of "Pneumonia" from January 1, 2001 to December 31, 2015. The only document types we studied were original articles and reviews, analyzing descriptive indicators by five-year periods and the scientific production by country, adjusting for population, economic, and research-related parameters. RESULTS: A total of 22,694 references were retrieved. The number of publications increased steadily over time, from 981 publications in 2001 to 1977 in 2015 (R = 0.956). The most productive country was the USA (38.49%), followed by the UK (7.18%) and Japan (5.46%). Research production from China increased by more than 1000%. By geographical area, North America (42.08%) and Europe (40.79%) were most dominant. Scientific production in low- and middle-income countries more than tripled, although their overall contribution to the field remained limited (< 15%). Overall, 18.8% of papers were the result of an international collaboration, although this proportion was much higher in sub-Saharan Africa (46.08%) and South Asia (23.43%). According to the specific MeSH terms used, articles focused mainly on "Pneumonia, Bacterial" (19.99%), followed by "Pneumonia, Pneumococcal" (7.02%) and "Pneumonia, Ventilator-Associated" (6.79%). CONCLUSIONS: Pneumonia research increased steadily over the 15-year study period, with Europe and North America leading scientific production. About a fifth of all papers reflected international collaborations, and these were most evident in papers from sub-Saharan Africa and South Asia.
2Clinical and translational research in pneumocystis and pneumocystis pneumonia.PubMed
L Huang
Parasite. 2011 Feb;18(1):3-11. doi: 10.1051/parasite/2011181003.
Pneumocystis pneumonia (PcP) remains a significant cause of morbidity and mortality in immunocompromised persons, especially those with human immunodeficiency virus (HIV) infection. Pneumocystis colonization is described increasingly in a wide range of immunocompromised and immunocompetent populations and associations between Pneumocystis colonization and significant pulmonary diseases such as chronic obstructive pulmonary disease (COPD) have emerged. This mini-review summarizes recent advances in our clinical understanding of Pneumocystis and PcP, describes ongoing areas of clinical and translational research, and offers recommendations for future clinical research from researchers participating in the "First centenary of the Pneumocystis discovery".
3Challenges and recommendations for addressing under-five pneumonia morbidity and mortality in Nigeria.PubMed
Chidi Okafor, Abimbola Olaniran, Elisabeth Darj
Afr Health Sci. 2023 Jun;23(2):193-201. doi: 10.4314/ahs.v23i2.21.
BACKGROUND: Pneumonia is a severe infection and one of the most common causes of mortality among children under five years of age, when not appropriately managed. Infection of the lungs by bacteria, viruses, or fungi and consequent inflammation may lead to cough and difficult breathing. Some of the key predisposing factors are malnutrition and air pollution. WHO reports that Africa has the highest burden of global child mortality, and 16% of all deaths in pneumonia, were children under five years of age in 2016. OBJECTIVES: This study aimed to explore how health providers perceive pneumonia as a cause of under-five mortality in Nigeria. METHODS: A qualitative study design with in-depth interviews and focus group discussions was used to explore and understand nurses and pediatricians' views regarding the pneumonia situation, vaccinations, and preventive suggestions to reduce under five pneumonia deaths in Nigeria. RESULTS: Two themes and four categories emerged: participant's anxiety over the situation, their views on impediments, current policies and strategies, and suggestions on addressing severe pneumonia. CONCLUSIONS: The results from this study highlight contextual issues playing major roles in pneumonia mortality among children in Nigeria, which will need approaches on several levels to address them.
4Mapping pneumonia research: A systematic analysis of UK investments and published outputs 1997-2013.PubMed
Michael G Head, Joseph R Fitchett, Marie-Louise Newell, et al.
EBioMedicine. 2015 Jul 4;2(9):1193-9. doi: 10.1016/j.ebiom.2015.06.024. eCollection 2015 Sep.
BACKGROUND: The burden of pneumonia continues to be substantial, particularly among the poorest in global society. We describe here the trends for UK pneumonia R&D investment and published outputs, and correlate with 2013 global mortality. METHODS: Data related to awards to UK institutions for pneumonia research from 1997 to 2013 were systematically sourced and categorised by disease area and type of science. Investment was compared to mortality figures in 2010 and 2013 for pneumonia, tuberculosis and influenza. Investment was also compared to publication data. RESULTS: Of all infectious disease research between 2011 and 2013 (£917.0 million), £28.8 million (3.1%) was for pneumonia. This was an absolute and proportionate increase from previous time periods. Translational pneumonia research (33.3%) received increased funding compared with 1997-2010 where funding was almost entirely preclinical (87.5%, here 30.9%), but high-burden areas such as paediatrics, elderly care and antimicrobial resistance received little investment. Annual investment remains volatile; publication temporal trends show a consistent increase. When comparing investment to global burden with a novel 'investment by mortality observed' metric, tuberculosis (£48.36) and influenza (£484.21) receive relatively more funding than pneumonia (£43.08), despite investment for pneumonia greatly increasing in 2013 compared to 2010 (£7.39). Limitations include a lack of private sector data and the need for careful interpretation of the comparisons with burden, plus categorisation is subjective. CONCLUSIONS: There has been a welcome increase for pneumonia funding awarded to UK institutions in 2011-2013 compared with 1997-2010, along with increases for more translational research. Published outputs relating to pneumonia rose steadily from 1997 to 2013. Investment relative to mortality for pneumonia has increased, but it remains low compared to other respiratory infections and clear inequities remain. Analyses that measure investments in pneumonia can provide an insight into funding trends and research gaps. RESEARCH IN CONTEXT: Pneumonia continues to be a high-burden illness around the globe. This paper shows that although research funding is increasing in the UK (between 1997 and 2013), it remains poorly funded compared to other important respiratory infectious diseases such as tuberculosis and influenza. Publications about pneumonia have been steadily increasing over time, indicating continuing academic and clinical interest in the topic. Though global mortality of pneumonia is declining, it should still be an area of high priority for funders, policymakers and researchers.
5Long-term prognosis in community-acquired pneumonia.PubMed
Marcos I Restrepo, Paola Faverio, Antonio Anzueto
Curr Opin Infect Dis. 2013 Apr;26(2):151-8. doi: 10.1097/QCO.0b013e32835ebc6d.
PURPOSE OF REVIEW: Pneumonia is considered the leading infectious diseases cause of death and the seventh leading cause of death overall in the US. There is significant interest in understanding the relationship between community-acquired pneumonia (CAP) and mortality. RECENT FINDINGS: Most clinical studies examining patients with CAP have used an arbitrary in-hospital or 30-day mortality as a short-term mortality clinical end point. However, long-term mortality (arbitrary >3 months) factors, incidence, prediction, and implications on patient care are important issues that require further evaluation in patients with CAP. This review focuses on the most recent literature assessing the importance and the frequency of long-term associated outcomes in patients with CAP, the risk factors, and possible implications for future strategies. Multiple risk factors that include age, sex, comorbid conditions, type of pneumonia, and severity of illness are associated with higher long-term mortality. In addition, several biomarkers were demonstrated to be independently associated with long-term mortality. SUMMARY: Despite advances in the understanding of long-term mortality among CAP patients, there is still a high unacceptable long-term mortality. Public health programs should address this important gap, considering the high level of complexity factors in patients with CAP.